Biolinerx LTD. 6-K Filing
Ticker: BLRX · Form: 6-K · Filed: Nov 24, 2025 · CIK: 1498403
Sentiment: neutral
Filing Stats: 289 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2025-11-24 07:00:17
Filing Documents
- zk2534058.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 355KB
- exhibit_2.htm (EX-99) — 431KB
- exhibit_3.htm (EX-99) — 247KB
- image0.jpg (GRAPHIC) — 27KB
- image00001.jpg (GRAPHIC) — 35KB
- 0001178913-25-003941.txt ( ) — 1130KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On November 24, 2025, the Registrant issued a press release announcing its financial results for the three and nine months ended September 30, 2025. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of September 30, 2025 and for the three and nine months then ended. Attached hereto are the following exhibits: Exhibit 1: Registrant's press release dated November 24, 2025; Exhibit 2: Registrant's condensed consolidated interim financial statements as of September 30, 2025 and for the three and nine months then ended; and Exhibit 3: Registrant's operating and financial review as of September 30, 2025 and for the three and nine months then ended. This Form 6-K, the text under the heading "Financial Results for the Quarter Ended September 30, 2025" in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: November 24, 2025